Publicly-traded pharmaceutical giant Roche acquired Stratos Genomics, a Seattle DNA sequencing startup, reported GeekWire.
Founded in 2007, Stratos’ technology is called Sequencing By Expansion (SBX), which converts DNA into more easily-read polymer, making it cheaper and faster to sequence DNA, according to the company.
Stratos had raised more than $60 million, according to PitchBook, including a $20 million round from Fisk Ventures in 2018. Roche was an early investor via its Roche Ventures arm.
“We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche,” Thomas Schinecker, CEO Roche Diagnostics, said in a statement.
Terms of the deal were not disclosed. Stratos will continue operating out of Seattle under the name Roche Diagnostics Seattle. The company originally spun out of Stratos Group. It has 60 employees, according to LinkedIn. Its chairman is Lee Huntsman, a professor emeritus at the University of Washington.
“We are thrilled to join the Roche family, which will allow us to combine our unique Sequencing by Expansion chemistry with the Roche nanopore sequencer,” said Mark Kokoris, President, CEO, and co-founder at Stratos Genomics, in a statement. “With our combined expertise and complementary technologies, we are well-positioned to open the path to deliver scalable, high-performance sequencing to clinicians and researchers.”
Full Content: Geek Wire
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI